Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells.

S C Dixon1, E A Kruger, K S Bauer

  • 1Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Cancer Chemotherapy and Pharmacology
|June 5, 1999
PubMed
Summary

Thalidomide increases prostate-specific antigen (PSA) secretion and shows cytostatic effects in prostate cancer cells, potentially modulating angiogenesis-related genes like vitronectin.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-in-human phase 0 study of <sup>111</sup>In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging.

Journal of translational science·2019
Same author

ANG1005 for breast cancer brain metastases: correlation between <sup>18</sup>F-FLT-PET after first cycle and MRI in response assessment.

Breast cancer research and treatment·2016
Same author

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.

International journal of cancer·2016
Same author

Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2015
Same author

A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib.

United European gastroenterology journal·2015
Same author

Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium.

British journal of cancer·2015

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Thalidomide exhibits antiangiogenic properties, with potential applications in treating angiogenesis-dependent cancers.
  • Its precise antiangiogenic mechanisms and effects on tumor gene expression remain largely unelucidated.
  • Preclinical studies have led to Phase II trials for various cancers, including prostate cancer.

Purpose of the Study:

  • To investigate thalidomide's effects on prostate-specific antigen (PSA) secretion in prostate cancer cells.
  • To assess thalidomide's impact on the growth and viability of human prostate cancer cell lines.
  • To analyze differential gene expression profiles in thalidomide-treated prostate cancer cells.

Main Methods:

  • Utilized human androgen-dependent (LNCaP) and androgen-independent (PC-3) prostate carcinoma cell lines.

Related Experiment Videos

  • Incubated cells with thalidomide at concentrations of 0.6, 6, or 60 microg/mL for 5-6 days.
  • Measured secreted PSA via ELISA, assessed cell viability, and analyzed gene expression using cDNA arrays.

    • Main Results:

    • Thalidomide significantly increased PSA/cell levels in LNCaP cells across all tested concentrations.
    • A cytostatic effect was observed in LNCaP cells; however, thalidomide had minimal impact on PC-3 cell viability.
    • Preliminary gene expression analysis suggested thalidomide may upregulate or downregulate angiogenesis-related genes, such as vitronectin.

    Conclusions:

    • Thalidomide demonstrates nontoxic, cytostatic activity in LNCaP cells and upregulates PSA secretion in vitro.
    • Preliminary findings suggest thalidomide may modulate angiogenic pathways through proteins like vitronectin, potentially linking its antiangiogenic activity to vascular integrin modulation.